Feb. 20 at 4:20 PM
$GRAL GRAIL -47% - Shares plunged after announcing topline results from the randomized NHS-Galleri trial, where the primary endpoint of a statistically significant reduction in Stage III-IV cancers was not met. While the study showed a favorable trend in a pre-specified group of 12 high-mortality cancers and reported meaningful reductions in Stage IV diagnoses with sequential screening, investors focused on the missed primary goal. The company said the Galleri test still demonstrated potential to shift cancer detection to earlier stages and reduce emergency presentations, and it plans further analysis with detailed data expected at the ASCO 2026 meeting.
Copart (
$CPRT) -6% - Shares dipped after FQ2 results disappointed, showing revenue down 3.6% Y/Y to
$1.12B despite pricing gains and record ASPs. Global service volumes declined 8% (3.6% ex-CAT), and U.S. insurance units fell 10.7%, with margin pressure and higher expenses fueling the negative reaction despite core operationa
